Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z.

Dis Model Mech. 2015 Jan;8(1):45-56. doi: 10.1242/dmm.018168. Epub 2014 Nov 27.

2.

Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.

Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, Alexander D, Wong KK, Van Dyke T.

Cancer Res. 2012 Nov 15;72(22):5921-33. doi: 10.1158/0008-5472.CAN-12-0736. Epub 2012 Sep 11.

3.

The New York policy on smoking in addiction treatment: findings after 1 year.

Guydish J, Tajima B, Kulaga A, Zavala R, Brown LS, Bostrom A, Ziedonis D, Chan M.

Am J Public Health. 2012 May;102(5):e17-25. doi: 10.2105/AJPH.2011.300590. Epub 2012 Mar 15.

4.

A preliminary study of the effects of individual patient-level feedback in outpatient substance abuse treatment programs.

Crits-Christoph P, Ring-Kurtz S, Hamilton JL, Lambert MJ, Gallop R, McClure B, Kulaga A, Rotrosen J.

J Subst Abuse Treat. 2012 Apr;42(3):301-9. doi: 10.1016/j.jsat.2011.09.003. Epub 2011 Oct 29.

5.

Mesothelioma of tunica vaginalis of "uncertain malignant potential" - an evolving concept: case report and review of the literature.

Trpkov K, Barr R, Kulaga A, Yilmaz A.

Diagn Pathol. 2011 Aug 25;6:78. doi: 10.1186/1746-1596-6-78. Review.

6.

Program, counselor, and patient variability in the alliance: a multilevel study of the alliance in relation to substance use outcomes.

Crits-Christoph P, Hamilton JL, Ring-Kurtz S, Gallop R, McClure B, Kulaga A, Rotrosen J.

J Subst Abuse Treat. 2011 Jun;40(4):405-13. doi: 10.1016/j.jsat.2011.01.003. Epub 2011 Feb 23.

7.

A randomized controlled study of a web-based performance improvement system for substance abuse treatment providers.

Crits-Christoph P, Ring-Kurtz S, McClure B, Temes C, Kulaga A, Gallop R, Forman R, Rotrosen J.

J Subst Abuse Treat. 2010 Apr;38(3):251-62. doi: 10.1016/j.jsat.2010.01.001. Epub 2010 Feb 8.

8.

Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.

Hien DA, Jiang H, Campbell AN, Hu MC, Miele GM, Cohen LR, Brigham GS, Capstick C, Kulaga A, Robinson J, Suarez-Morales L, Nunes EV.

Am J Psychiatry. 2010 Jan;167(1):95-101. doi: 10.1176/appi.ajp.2009.09091261. Epub 2009 Nov 16.

9.

Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders.

Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell AN, Cohen LR, Miele GM, Killeen T, Brigham GS, Zhang Y, Hansen C, Hodgkins C, Hatch-Maillette M, Brown C, Kulaga A, Kristman-Valente A, Chu M, Sage R, Robinson JA, Liu D, Nunes EV.

J Consult Clin Psychol. 2009 Aug;77(4):607-19. doi: 10.1037/a0016227.

10.

Glycerol-3-phosphate acyltransferases gat1p and gat2p are microsomal phosphoproteins with differential contributions to polarized cell growth.

Bratschi MW, Burrowes DP, Kulaga A, Cheung JF, Alvarez AL, Kearley J, Zaremberg V.

Eukaryot Cell. 2009 Aug;8(8):1184-96. doi: 10.1128/EC.00085-09. Epub 2009 Jun 12.

11.

A feasibility study of a web-based performance improvement system for substance abuse treatment providers.

Forman R, Crits-Christoph P, Kaynak O, Worley M, Hantula DA, Kulaga A, Rotrosen J, Chu M, Gallop R, Potter J, Muchowski P, Brower K, Strobbe S, Magruder K, Chellis AH, Clodfelter T, Cawley M.

J Subst Abuse Treat. 2007 Dec;33(4):363-71. Epub 2007 May 14.

Supplemental Content

Loading ...
Support Center